gepotidacin + placebo (GSK)

Gepotidacin (GSK2140944) is a novel, first-in-class triazaacenaphthylene antibiotic developed by GSK. It functions as a bacterial topoisomerase inhibitor, uniquely targeting DNA gyrase and topoisomerase IV by stabilizing the precleavage topoisomerase-DNA complex and generating single-strand breaks, a mechanism distinct from fluoroquinolones. This specific entry refers to the evaluation of gepotidacin in comparison to a placebo, particularly in the context of respiratory tract infections, an indication for which development has largely been deprioritized in favor of Phase III programs for uncomplicated urinary tract infections and urogenital gonorrhea. The drug has demonstrated in vitro activity against key respiratory pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).

Other names

gepotidacin